Symbols / BMEA Stock $1.73 -8.47% Biomea Fusion, Inc.

Healthcare • Biotechnology • United States • NMS
BMEA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Michael J. M. Hitchcock Ph.D.
Exch · Country NMS · United States
Market Cap 125.08M
Enterprise Value 70.86M
Income -61.80M
Sales —
FCF (ttm) -42.03M
Book/sh 0.41
Cash/sh 0.77
Employees 41
Insider 10d —
IPO Apr 16, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.63
PEG —
P/S —
P/B 4.23
P/C —
EV/EBITDA -0.89
EV/Sales —
Quick Ratio 5.03
Current Ratio 5.23
Debt/Eq 5.38
LT Debt/Eq —
EPS (ttm) -1.18
EPS next Y -1.06
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-03-24
ROA -73.38%
ROE -152.35%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 72.30M
Shs Float 67.44M
Insider Own 7.23%
Instit Own 37.34%
Short Float 23.17%
Short Ratio 7.44
Short Interest 14.09M
52W High 3.08
vs 52W High -43.83%
52W Low 0.87
vs 52W Low 98.39%
Beta -0.27
Impl. Vol. 2.67%
Rel Volume 0.94
Avg Volume 1.42M
Volume 1.33M
Target (mean) $7.17
Tgt Median $6.50
Tgt Low $4.00
Tgt High $12.00
# Analysts 6
Recom None
Prev Close $1.89
Price $1.73
Change -8.47%
About

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.17
Mean price target
2. Current target
$1.73
Latest analyst target
3. DCF / Fair value
$-10.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.73
Low
$4.00
High
$12.00
Mean
$7.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-08 main D. Boral Capital Buy → Buy $12
2026-03-27 main Citigroup Buy → Buy $7
2026-03-25 main D. Boral Capital Buy → Buy $12
2026-01-13 main D. Boral Capital Buy → Buy $12
2025-11-10 main Citigroup Buy → Buy $6
2025-11-05 main D. Boral Capital Buy → Buy $12
2025-10-27 main D. Boral Capital Buy → Buy $16
2025-10-07 main D. Boral Capital Buy → Buy $16
2025-10-03 main D. Boral Capital Buy → Buy $16
2025-08-28 init Jefferies — → Buy $5
2025-08-11 main Citigroup Buy → Buy $7
2025-08-06 main Scotiabank Sector Outperform → Sector Outperform $10
2025-08-06 main D. Boral Capital Buy → Buy $16
2025-07-21 main D. Boral Capital Buy → Buy $16
2025-07-16 main Citigroup Buy → Buy $9
2025-06-24 main D. Boral Capital Buy → Buy $16
2025-06-18 main D. Boral Capital Buy → Buy $16
2025-06-13 main D. Boral Capital Buy → Buy $16
2025-05-15 main D. Boral Capital Buy → Buy $16
2025-05-06 main D. Boral Capital Buy → Buy $16
News
RSS: Latest BMEA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-31 ERDTMANN RAINER M President — 150,600 $0.00 $0
2025-12-11 ERDTMANN RAINER M President — 30,000 $1.43 $42,999
2025-12-02 HITCHCOCK MICHAEL J.M. Chief Executive Officer — 100,000 $0.99 $99,180
2025-12-01 ERDTMANN RAINER M President — 50,000 $1.05 $54,552
2025-01-31 ERDTMANN RAINER M President — 70,000 $0.00 $0
2024-11-29 VALLE FRANCO Chief Financial Officer — 495 $6.15 $3,046
2024-09-30 HITCHCOCK MICHAEL J.M. Director — 10,000 $10.06 $100,600
2024-06-11 VALLE FRANCO Chief Financial Officer — 12,509 $4.43 $55,361
2024-05-31 VALLE FRANCO Chief Financial Officer — 4,448 $10.52 $46,793
2024-05-31 FRIAS JUAN PABLO Officer — 349 $8.94 $3,121
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
81.31
-43.56%
144.07
+14.22%
126.14
+50.82%
83.63
Research And Development
61.98
-47.51%
118.08
+15.15%
102.55
+63.52%
62.71
Selling General And Administration
19.33
-25.62%
25.98
+10.16%
23.59
+12.75%
20.92
General And Administrative Expense
19.33
-25.62%
25.98
+10.16%
23.59
+12.75%
20.92
Other Gand A
19.33
-25.62%
25.98
+10.16%
23.59
+12.75%
20.92
Total Expenses
81.31
-43.56%
144.07
+14.22%
126.14
+50.82%
83.63
Operating Income
-81.31
+43.56%
-144.07
-14.22%
-126.14
-50.82%
-83.63
Total Operating Income As Reported
-83.51
+42.03%
-144.07
-14.22%
-126.14
-50.82%
-83.63
EBITDA
-79.90
+43.86%
-142.32
-14.20%
-124.62
-50.25%
-82.94
Normalized EBITDA
-97.55
+31.46%
-142.32
-14.20%
-124.62
-50.25%
-82.94
Reconciled Depreciation
1.41
-19.39%
1.75
+15.38%
1.51
+119.25%
0.69
EBIT
-81.31
+43.56%
-144.07
-14.22%
-126.14
-50.82%
-83.63
Total Unusual Items
17.65
0.00
0.00
—
Total Unusual Items Excluding Goodwill
17.65
0.00
0.00
—
Special Income Charges
-2.21
0.00
0.00
—
Impairment Of Capital Assets
2.21
0.00
0.00
—
Net Income
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Pretax Income
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Net Non Operating Interest Income Expense
1.86
-67.08%
5.64
-36.44%
8.88
+391.69%
1.81
Net Interest Income
1.86
-67.08%
5.64
-36.44%
8.88
+391.69%
1.81
Interest Income Non Operating
1.86
-67.08%
5.64
-36.44%
8.88
+391.69%
1.81
Interest Income
1.86
-67.08%
5.64
-36.44%
8.88
+391.69%
1.81
Other Income Expense
17.65
—
—
—
Gain On Sale Of Security
19.86
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Net Income From Continuing Operation Net Minority Interest
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Net Income From Continuing And Discontinued Operation
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Net Income Continuous Operations
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Normalized Income
-79.45
+42.61%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Net Income Common Stockholders
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Diluted EPS
—
-3.83
-11.34%
-3.44
-22.86%
-2.80
Basic EPS
—
-3.83
-11.34%
-3.44
-22.86%
-2.80
Basic Average Shares
—
36.11
+5.86%
34.11
+16.52%
29.27
Diluted Average Shares
—
36.11
+5.86%
34.11
+16.52%
29.27
Diluted NI Availto Com Stockholders
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
58.57
-26.73%
79.94
-60.02%
199.93
+54.61%
129.31
Current Assets
58.05
-15.05%
68.33
-61.86%
179.18
+52.08%
117.82
Cash Cash Equivalents And Short Term Investments
55.81
-4.23%
58.28
-67.05%
176.87
+56.45%
113.05
Cash And Cash Equivalents
55.81
-4.23%
58.28
-67.05%
176.87
+58.06%
111.90
Other Short Term Investments
—
—
0.00
-100.00%
1.15
Prepaid Assets
—
—
—
—
Other Current Assets
2.24
-77.74%
10.05
+334.25%
2.31
-51.47%
4.77
Total Non Current Assets
0.52
-95.50%
11.61
-44.06%
20.75
+80.59%
11.49
Net PPE
0.15
-98.56%
10.62
-28.61%
14.87
+86.10%
7.99
Gross PPE
1.16
-92.15%
14.80
-14.49%
17.30
+94.25%
8.91
Accumulated Depreciation
-1.01
+75.86%
-4.18
-71.90%
-2.43
-165.39%
-0.92
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.58
+0.00%
0.58
+7.24%
0.54
+18.46%
0.46
Construction In Progress
—
0.00
-100.00%
0.00
-99.87%
3.17
Other Properties
0.10
-99.05%
10.78
-20.54%
13.57
+202.68%
4.48
Leases
0.48
-85.98%
3.44
+7.64%
3.19
+298.88%
0.80
Investments And Advances
—
—
0.00
0.00
Other Non Current Assets
0.37
-62.65%
0.99
-83.18%
5.87
+67.99%
3.50
Total Liabilities Net Minority Interest
29.02
+2.31%
28.36
-7.58%
30.69
+47.78%
20.77
Current Liabilities
11.10
-48.78%
21.67
-5.19%
22.86
+19.68%
19.10
Payables And Accrued Expenses
9.47
-51.16%
19.39
-4.01%
20.20
+13.20%
17.85
Payables
3.23
-75.00%
12.93
+88.76%
6.85
+0.37%
6.83
Accounts Payable
3.23
-75.00%
12.93
+88.76%
6.85
+0.37%
6.83
Current Accrued Expenses
6.24
-3.42%
6.46
-51.62%
13.35
+21.14%
11.02
Current Debt And Capital Lease Obligation
1.46
-29.73%
2.08
-15.69%
2.47
+299.03%
0.62
Current Capital Lease Obligation
1.46
-29.73%
2.08
-15.69%
2.47
+299.03%
0.62
Other Current Liabilities
0.17
-16.75%
0.20
+5.73%
0.19
-69.81%
0.64
Total Non Current Liabilities Net Minority Interest
17.92
+167.77%
6.69
-14.53%
7.83
+369.71%
1.67
Long Term Debt And Capital Lease Obligation
0.13
-98.09%
6.69
-14.53%
7.83
+369.71%
1.67
Long Term Capital Lease Obligation
0.13
-98.09%
6.69
-14.53%
7.83
+369.71%
1.67
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Common Stock Equity
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Capital Stock
0.01
+75.00%
0.00
+0.00%
0.00
+33.33%
0.00
Common Stock
0.01
+75.00%
0.00
+0.00%
0.00
+33.33%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
72.30
+99.11%
36.31
+1.24%
35.87
+21.33%
29.56
Ordinary Shares Number
72.30
+99.11%
36.31
+1.24%
35.87
+21.33%
29.56
Additional Paid In Capital
478.59
+9.06%
438.82
+4.97%
418.06
+74.11%
240.11
Retained Earnings
-449.05
-15.96%
-387.25
-55.63%
-248.82
-89.12%
-131.57
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-0.00
Other Equity Adjustments
—
—
—
-0.00
Total Equity Gross Minority Interest
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Total Capitalization
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Working Capital
46.95
+0.62%
46.66
-70.15%
156.32
+58.35%
98.72
Invested Capital
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Total Debt
1.59
-81.88%
8.77
-14.81%
10.30
+350.59%
2.29
Capital Lease Obligations
1.59
-81.88%
8.77
-14.81%
10.30
+350.59%
2.29
Net Tangible Assets
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Tangible Book Value
29.55
-42.70%
51.57
-69.53%
169.24
+55.92%
108.54
Derivative Product Liabilities
17.79
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-70.37
+41.31%
-119.89
-24.12%
-96.59
-54.75%
-62.42
Cash Flow From Continuing Operating Activities
-70.37
+41.31%
-119.89
-24.12%
-96.59
-54.75%
-62.42
Net Income From Continuing Operations
-61.80
+55.36%
-138.43
-18.06%
-117.25
-43.29%
-81.83
Depreciation Amortization Depletion
1.41
-19.39%
1.75
+15.38%
1.51
+119.25%
0.69
Depreciation
1.41
-19.39%
1.75
+15.38%
1.51
+119.25%
0.69
Depreciation And Amortization
1.41
-19.39%
1.75
+15.38%
1.51
+119.25%
0.69
Other Non Cash Items
1.85
-34.92%
2.84
+5.66%
2.69
+370.40%
0.57
Stock Based Compensation
9.52
-50.14%
19.09
+35.12%
14.13
+36.72%
10.34
Asset Impairment Charge
2.21
0.00
0.00
—
Operating Gains Losses
-19.86
—
—
—
Gain Loss On Investment Securities
-19.86
—
—
—
Change In Working Capital
-3.70
+28.17%
-5.15
-320.94%
2.33
-69.62%
7.67
Change In Prepaid Assets
7.82
+201.00%
-7.74
-412.27%
2.48
+243.65%
-1.73
Change In Payables And Accrued Expense
-9.96
-1155.36%
-0.79
-117.83%
4.45
-62.54%
11.87
Change In Accrued Expense
-0.26
+96.29%
-6.88
-464.85%
1.89
-78.84%
8.91
Change In Payable
-9.70
-259.33%
6.09
+137.63%
2.56
-13.45%
2.96
Change In Account Payable
-9.70
-259.33%
6.09
+137.63%
2.56
-13.45%
2.96
Change In Other Current Assets
0.62
-87.33%
4.88
+307.12%
-2.36
-23.13%
-1.92
Change In Other Current Liabilities
-2.18
-45.04%
-1.50
+32.93%
-2.24
-296.11%
-0.56
Investing Cash Flow
0.00
+100.00%
-0.36
+83.69%
-2.22
-108.12%
27.34
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.36
+83.69%
-2.22
-108.12%
27.34
Net PPE Purchase And Sale
0.00
+100.00%
-0.36
+89.26%
-3.37
-227.18%
-1.03
Purchase Of PPE
0.00
+100.00%
-0.36
+89.26%
-3.37
-227.18%
-1.03
Capital Expenditure
—
-0.36
+89.26%
-3.37
-227.18%
-1.03
Net Investment Purchase And Sale
0.00
0.00
-100.00%
1.15
-95.95%
28.37
Purchase Of Investment
—
—
0.00
0.00
Sale Of Investment
0.00
0.00
-100.00%
1.15
-95.95%
28.37
Financing Cash Flow
67.90
+3970.98%
1.67
-98.98%
163.80
+13120.18%
1.24
Cash Flow From Continuing Financing Activities
67.90
+3970.98%
1.67
-98.98%
163.80
+13120.18%
1.24
Net Issuance Payments Of Debt
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
67.75
0.00
-100.00%
161.80
0.00
Proceeds From Stock Option Exercised
0.16
-90.47%
1.67
-16.39%
2.00
+61.02%
1.24
Changes In Cash
-2.47
+97.92%
-118.59
-282.48%
64.99
+292.06%
-33.84
Beginning Cash Position
58.65
-66.91%
177.24
+57.89%
112.25
-23.16%
146.09
End Cash Position
56.18
-4.21%
58.65
-66.91%
177.24
+57.89%
112.25
Free Cash Flow
-70.37
+41.48%
-120.26
-20.30%
-99.96
-57.55%
-63.45
Amortization Of Securities
0.00
0.00
-100.00%
0.00
-99.31%
0.14
Common Stock Issuance
67.75
0.00
-100.00%
161.80
0.00
Issuance Of Capital Stock
67.75
0.00
-100.00%
161.80
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category